RecruitingPHASE2, PHASE3NCT07210723
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Studying Familial dilated cardiomyopathy with conduction defect due to LMNA mutation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kardigan, Inc.
- Intervention
- danicamtiv(drug)
- Enrollment
- 332 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (26)
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Cedars Sinai, Los Angeles, California, United States
- UCSF, San Francisco, California, United States
- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Louisiana State University (LSU) Health Sciences Center, New Orleans, Louisiana, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Aarhus University Hospital, Aarhus, Denmark
- AP-HP Hopital Pitie-Salpetriere, Paris, France
- Hospital Universitario Vall d'Hebron, Horta-Guinardó, Barcelona, Spain
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07210723 on ClinicalTrials.gov